Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3917455 | 0.86 | KDM4E (0.46) | KDM4EALDH1A1SMN1; SMN2NUDT1 | |
| SCHEMBL3909002 | 0.81 | ABL1 (0.45) | — | |
| SCHEMBL3909975 | 0.80 | KDM4E (0.57) | KDM4EALDH1A1SMN1; SMN2NUDT1CYP1A2 | |
| SCHEMBL3919967 | 0.78 | KDM4E (0.52) | KDM4EALDH1A1SMN1; SMN2NUDT1 | |
| SCHEMBL3918178 | 0.78 | KDM4E (0.43) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3913834 | 0.77 | KDM4E (0.46) | KDM4EALDH1A1SMN1; SMN2NUDT1 | |
| SCHEMBL3911140 | 0.77 | KDM4E (0.44) | KDM4EALDH1A1SMN1; SMN2NUDT1CYP1A2 | |
| SCHEMBL3914206 | 0.76 | SMN1; SMN2 (0.43) | KDM4EALDH1A1SMN1; SMN2NUDT1F2 | |
| SCHEMBL3908991 | 0.75 | CYP2A6 (0.50) | KDM4EALDH1A1SMN1; SMN2NUDT1 | |
| SCHEMBL3909959 | 0.75 | CYP11B1 (0.39) | KDM4EALDH1A1SMN1; SMN2F2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524860-B2 | Antibacterial agents | PFIZER INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-20080021059-A1 | Antibacterial Agents | PFIZER INC. (US) | 2008-01-24 | — | — | US | disclosed |
| EP-1799680-A2 | TRIAZOLOPYRIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | Warner-Lambert Company LLC (US) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006038116-A2 | TRIAZOLOPYRIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021059-A1 | Antibacterial Agents | CLPP, QDPR, CLSPN | KDM4E 3745/4885ALDH1A1 3118/4885SMN1; SMN2 4497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.